Suppr超能文献

硫喷妥钠与去骨瓣减压术作为颅内压治疗的最后手段在蛛网膜下腔出血中的应用:功能恢复触手可及?

Thiopental and decompressive craniectomy as last-tier ICP-treatments in aneurysmal subarachnoid hemorrhage: is functional recovery within reach?

机构信息

Department of Medical Sciences, Section of Neurosurgery, Uppsala University, 751 85, Uppsala, Sweden.

出版信息

Neurosurg Rev. 2023 Sep 7;46(1):231. doi: 10.1007/s10143-023-02138-6.

Abstract

The study aimed to investigate the indication and functional outcome after barbiturates and decompressive craniectomy (DC) as last-tier treatments for elevated intracranial pressure (ICP) in aneurysmal subarachnoid hemorrhage (aSAH). This observational study included 891 aSAH patients treated at a single center between 2008 and 2018. Data on demography, admission status, radiology, ICP, clinical course, and outcome 1-year post-ictus were collected. Patients treated with thiopental (barbiturate) and DC were the main target group.Thirty-nine patients (4%) were treated with thiopental alone and 52 (6%) with DC. These patients were younger and had a worse neurological status than those who did not require these treatments. Before thiopental, the median midline shift was 0 mm, whereas basal cisterns were compressed/obliterated in 66%. The median percentage of monitoring time with ICP > 20 mmHg immediately before treatment was 38%, which did not improve after 6 h of infusion. Before DC, the median midline shift was 10 mm, and the median percentage of monitoring time with ICP > 20 mmHg before DC was 56%, which both significantly improved postoperatively. At follow-up, 52% of the patients not given thiopental or operated with DC reached favorable outcome, whereas this occurred in 10% of the thiopental and DC patients.In summary, 10% of the aSAH cohort required thiopental, DC, or both. Thiopental and DC are important integrated last-tier treatment options, but careful patient selection is needed due to the risk of saving many patients into a state of suffering.

摘要

本研究旨在探讨巴比妥类药物和去骨瓣减压术(DC)作为颅内压(ICP)升高的最后治疗手段,在颅内动脉瘤性蛛网膜下腔出血(aSAH)中的适应证和功能预后。本观察性研究纳入了 2008 年至 2018 年期间在一家中心治疗的 891 例 aSAH 患者。收集了人口统计学、入院状态、影像学、ICP、临床病程和发病后 1 年的预后数据。接受硫喷妥钠(巴比妥类药物)和 DC 治疗的患者是主要的目标人群。39 例(4%)患者单独接受硫喷妥钠治疗,52 例(6%)患者接受 DC 治疗。这些患者比不需要这些治疗的患者更年轻,神经功能状态更差。在使用硫喷妥钠之前,中线移位的中位数为 0 毫米,而基底池受压/闭塞的比例为 66%。治疗前即刻 ICP>20mmHg 的监测时间中位数百分比为 38%,输注 6 小时后无改善。在进行 DC 之前,中线移位的中位数为 10 毫米,在进行 DC 之前 ICP>20mmHg 的监测时间中位数百分比为 56%,这两个指标在手术后均显著改善。在随访时,未接受硫喷妥钠或未行 DC 手术的患者中,52%达到了良好的结局,而硫喷妥钠和 DC 组的这一比例为 10%。总之,10%的 aSAH 患者需要接受硫喷妥钠、DC 或两者联合治疗。硫喷妥钠和 DC 是重要的综合最后治疗选择,但由于有使许多患者陷入痛苦状态的风险,需要谨慎选择患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa55/10485091/826849d3ce78/10143_2023_2138_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验